Home
    • Plans Blog Contact
    ELITE PHARMACEUTICALS INC /NV/ logo

    ELITE PHARMACEUTICALS INC /NV/

    ELTP
    Last price US$0.38
    Market cap US$396.0m
    12M price change -31.15%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    ELITE PHARMACEUTICALS INC /NV/ Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey. Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Bra Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for ELITE PHARMACEUTICALS INC /NV/ into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jun 29, 2026

    Quarterly result summary

    Revenue was $148.9M (+77% YoY). Income from operations was $49.1M (+151% YoY).

    Revenue $148.9M +77% YoY
    Income from operations $49.1M +151% YoY

    What changed

    • Revenue +77% YoY to $148.9M.
    • Income from operations +151% YoY to $49.1M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Jun 29, 2026 SEC filing 10-K Jun 29, 2026 SEC filing 10-Q Feb 17, 2026 SEC filing 8-K Feb 17, 2026 Earnings release Earnings release Feb 17, 2026 SEC filing 8-K Nov 14, 2025 Earnings release Earnings release Nov 14, 2025 SEC filing 10-Q Nov 14, 2025 SEC filing 8-K Aug 14, 2025 SEC filing EX-99.1 Aug 14, 2025 SEC filing 10-Q Aug 14, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    ELITE PHARMACEUTICALS INC /NV/ boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 3.60/5
    ELITE PHARMACEUTICALS INC /NV/ stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ELITE PHARMA... ELTP US$396.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.79/5
    ELITE PHARMACEUTICALS INC /NV/ commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ELITE PHARMA... ELTP US$396.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 2.57/5
    ELITE PHARMACEUTICALS INC /NV/ attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    ELITE PHARMA... ELTP US$396.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    ELITE PHARMACEUTICALS INC /NV/ logo

    ELITE PHARMACEUTICALS INC /NV/

    US$0.38

    US$0.388

    -0.0% vs price

    US$396.0m

    2.15%

    -31.15%